PRM-151

July 17, 2017July 17, 2017

Esbriet, Ofev Remain the Most Reliable Therapies for Idiopathic Pulmonary Fibrosis, Comparison Study Shows

The first two approved therapies for idiopathic pulmonary fibrosis (IPF), Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), are still the most reliable treatments among several approved and experimental therapies, according to a ... Read more

September 9, 2015November 5, 2015

Promedior Begins Phase 2 Clinical Trial for Novel IPF Treatment

Idiopathic Pulmonary Fibrosis, News

Promedior, a biotechnology company developing targeted therapeutics to treat a range of fibrotic diseases, announced the beginning of the second phase of their PRM-151 clinical trial in patients with Idiopathic Pulmonary Fibrosis ... Read more

June 8, 2015November 5, 2015

Promedior Announces Presentation Of Phase 2 Data On IPF Therapy PRM-151 In Treating Myelofibrosis

Idiopathic Pulmonary Fibrosis, News

Promedior Inc. a biotechnology company focused on advancing new therapeutics to address treatment for fibrosis, recently announced that Olga Pozdynakova of Brigham and Women’s Hospital Boston will be presenting further data on the firm’s ongoing Phase 2 clinical trial ... Read more